Table 3:
Other CAR T therapy trials in MM
| Baylor | U Penn | China | |
|---|---|---|---|
| Authors/presentation | Ramos et al, JCI 2016; 126:2588 | Garfall et al, JCI Insight, 2018; 3:e120505 | Guo et al, J Cell Immunol 2016, 2:28 |
| Target | Kappa light chain (CRL-1758 hybridoma) | ASCT + CTL019 | CD138 |
| n | 8 | 10 | 5 |
| vector | Retroviral vector | Lentiviral vector | Lentiviral vector |
| Costimulatory domain | CD28 | 4–1BB | 4–1BB (CD137) |
| Activation domain | CD3-zeta | CD3-zeta | CD3-zeta |
| conditioning | 3 patients without Cy; 5 with Cy | ASCT followed by CTL019 | various |
| Dosing | 9.2 to 19 × 107 CAR T cells/M2 | 4.4 × 108 (range 1.1 to 6 × 108) | 0.756 × 107 cytokine-induced killer cells/kg |
| Prior lines of treatment (median) | 1–5 | 2–10 | 5–18 |
| CRS | None | None | fever |
| Response | 5: SD; 3: NR | 2 patients significantly longer PFS (479 vs 181; 249 vs 127) | 4/5: stable disease |
| MRD | Not done | Not done | Not done |